Your browser doesn't support javascript.
loading
Analysis of the F2LR3 (PAR4) Single Nucleotide Polymorphism (rs773902) in an Indigenous Australian Population.
Ningtyas, Dian; Thomson, Russell J; Tarlac, Volga; Nagaraj, Shivashankar H; Hoy, Wendy; Mathews, John D; Foote, Simon J; Gardiner, Elizabeth E; Hamilton, Justin R; McMorran, Brendan J.
Afiliação
  • Ningtyas D; Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
  • Thomson RJ; Centre for Research in Mathematics and Data Science, School of Computer, Data and Mathematical Sciences, Western Sydney University, Parramatta, NSW, Australia.
  • Tarlac V; Australian Center for Blood Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Nagaraj SH; Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
  • Hoy W; Translational Research Institute, Brisbane, QLD, Australia.
  • Mathews JD; Centre for Chronic Disease, Faculty of Health, The University of Queensland, Brisbane, QLD, Australia.
  • Foote SJ; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
  • Gardiner EE; Menzies School of Health Research, Darwin, NT, Australia.
  • Hamilton JR; Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
  • McMorran BJ; Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Front Genet ; 11: 432, 2020.
Article em En | MEDLINE | ID: mdl-32425989
ABSTRACT
The F2RL3 gene encoding protease activated receptor 4 (PAR4) contains a single nucleotide variant, rs773902, that is functional. The resulting PAR4 variants, Thr120, and Ala120, are known to differently affect platelet reactivity to thrombin. Significant population differences in the frequency of the allele indicate it may be an important determinant in the ethnic differences that exist in thrombosis and hemostasis, and for patient outcomes to PAR antagonist anti-platelet therapies. Here we determined the frequency of rs773902 in an Indigenous Australian group comprising 467 individuals from the Tiwi Islands. These people experience high rates of renal disease that may be related to platelet and PAR4 function and are potential recipients of PAR-antagonist treatments. The rs773902 minor allele frequency (Thr120) in the Tiwi Islanders was 0.32, which is similar to European and Asian groups and substantially lower than Melanesians and some African groups. Logistic regression and allele distortion testing revealed no significant associations between the variant and several markers of renal function, as well as blood glucose and blood pressure. These findings suggest that rs773902 is not an important determinant for renal disease in this Indigenous Australian group. However, the relationships between rs773902 genotype and platelet and drug responsiveness in the Tiwi, and the allele frequency in other Indigenous Australian groups should be evaluated.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Genet Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Genet Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália